Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

被引：113

作者：

Milatovic, D ^{[1
]}

Schmitz, FJ ^{[1
]}

Verhoef, J ^{[1
]}

Fluit, AC ^{[1
]}

机构：

[1] Univ Utrecht Hosp, Eijkman Winkler Inst Med Microbiol, NL-3584 CX Utrecht, Netherlands

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 01期

关键词：

D O I：

10.1128/AAC.47.1.400-404.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycylcycline exhibited excellent activity against all gram-positive cocci (MICs at which 90% of the isolates tested were inhibited [MIC(90)s], less than or equal to1 mug/ml). In addition, it was also very potent against most members of the Enterobacteriaceae, with most MIC(90)s being less than or equal to2 mug/ml. Among the nonfermenters, Acinetobacter spp. and Stenotrophomonas maltophilia are included in the in vitro spectrum of tigecycline activity.

引用

页码：400 / 404

页数：5

共 17 条

[1] In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain [J].

Betriu, C ;

Rodríguez-Avial, I ;

Sánchez, BA ;

Gómez, M ;

Alvarez, J ;

Picazo, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :892-895

[2] In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases [J].

Biedenbach, DJ ;

Beach, ML ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) :173-177

[3] In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].

Boucher, HW ;

Wennersten, CB ;

Eliopoulos, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229

[4]

Chopra Ian, 2001, Current Opinion in Pharmacology, V1, P464, DOI 10.1016/S1471-4892(01)00081-9

[5] GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae:: preliminary guidelines and interpretive criteria [J].

Deshpande, LM ;

Gales, AC ;

Jones, RN .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (01) :29-35

[6] Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates [J].

Gales, AC ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :19-36

[7] Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens [J].

Goldstein, EJC ;

Citron, DM ;

Merriam, CV ;

Warren, Y ;

Tyrrell, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (10) :2747-2751

[8] Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936) [J].

Henwood, CJ ;

Gatward, T ;

Warner, M ;

James, D ;

Stockdale, MW ;

Spence, RP ;

Towner, KJ ;

Livermore, DM ;

Woodford, N .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) :479-487

[9] Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci [J].

Hoellman, DB ;

Pankuch, GA ;

Jacobs, MR ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1085-1088

[10] Susceptibilities of Mycoplasma hominis, M-pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones [J].

Kenny, GE ;

Cartwright, FD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (09) :2604-2608

← 1 2 →